Combination therapy in kidney cancer: The next revolution?

The Lancet Oncology

Volumn 16, Issue 15, 2015, Pages 1441-1442

  Buti, Sebastiano ^a   Bersanelli, Melissa ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; CABOZANTINIB; EVEROLIMUS; LENVATINIB; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN TYROSINE KINASE; SORAFENIB; SUNITINIB; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; QUINOLINE DERIVATIVE;

CANCER COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; ENZYME INHIBITION; HUMAN; IMMUNE SYSTEM; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY METASTASIS; MORTALITY; NOTE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; CARCINOMA, RENAL CELL; FEMALE; KIDNEY TUMOR; MALE; PATHOLOGY; SECONDARY;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; EVEROLIMUS; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; PHENYLUREA COMPOUNDS; QUINOLINES;

EID: 84960955915     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00325-3     Document Type: Note

References (9)

1. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015, for the CheckMate 025 Investigators, published online Sept 25. 10.1056/NEJMoa1510665.
2. Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 2015, published online Oct 16. http://dx.doi.org/S1470-2045(15)00290-9.
3. Molina AM, Feldman DR, Voss MH, et al. Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 2012, 118:1868-1876.
4. Patel PH, Senico PL, Curiel RE, Motzer RJ Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2009, 7:24-27.
5. Patnaik A, Ricart A, Cooper JS, et al. A phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies. Proc Am Soc Clin Oncol 2007, 25(suppl 18). abstr 3512.
6. Rosenberg JE, Weinberg VK, Claros C, et al. Phase I study of sorafenib and RAD001 for metastatic clear cell renal cell carcinoma. Proc Am Soc Clin Oncol 2008, 26(suppl 15). abstr 5109.
7. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
8. Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 2013, 14:552-562.
9. Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015, for the METEOR investigators, published online Sept 25. 10.1056/NEJMoa1510016.